Followers | 0 |
Posts | 1474 |
Boards Moderated | 0 |
Alias Born | 02/10/2022 |
![](https://investorshub.advfn.com/uicon/819441.png?cb=1655221156)
Thursday, June 02, 2022 9:44:50 AM
https://www.marketwatch.com/story/roche-repares-licensing-deal-includes-milestone-payments-worth-up-to-12-billion-2022-06-02
https://pulse2.com/repare-therapeutics-rptx-stock-price-why-it-increased-over-20-today/
https://www.postregister.com/businessreport/healthcare/repare-therapeutics-announces-a-worldwide-license-and-collaboration-agreement-with-roche-for-camonsertib-rp-3500/article_a6d38b6f-626d-51f5-a151-9e0e435be816.html
https://www.marketbeat.com/instant-alerts/nasdaq-rptx-a-buy-or-sell-right-now-2022-06/
![](http://media.giphy.com/media/l3fQf1OEAq0iri9RC/giphy.gif)
"Heck, last time I saw a stock like THIS rocketship, it landed on Planet JUPITER by lunchtime on Wall Street!"
Recent RPTX News
- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI • Business Wire • 06/26/2024 02:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:54 PM
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial • Business Wire • 06/10/2024 11:05:00 AM
- Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer • Business Wire • 06/04/2024 08:05:00 PM
- Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/03/2024 08:05:00 PM
- Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 • Business Wire • 05/29/2024 11:05:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/24/2024 08:06:52 PM
- Small Cap Massively Bid Following Key Q1 Earnings Beat • AllPennyStocks.com • 05/08/2024 02:10:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:15:55 PM
- Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results • Business Wire • 05/07/2024 08:05:00 PM
- DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE • Business Wire • 04/30/2024 11:05:00 AM
- Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition • Business Wire • 04/30/2024 11:05:00 AM
- Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition • Business Wire • 04/30/2024 11:05:00 AM
- Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors • Business Wire • 04/26/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:15:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:06:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 02:02:38 AM
- Repare Therapeutics to Participate in Two Upcoming Investor Conferences • Business Wire • 02/29/2024 12:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/28/2024 09:09:45 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 12:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 12:10:15 PM
- Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/28/2024 12:05:00 PM
- Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 • Business Wire • 02/15/2024 12:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 02:02:34 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:54:27 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM